

Mandip Singh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2008668/publications.pdf>

Version: 2024-02-01

145
papers

5,749
citations

66234

42
h-index

98622

67
g-index

149
all docs

149
docs citations

149
times ranked

7218
citing authors

#	ARTICLE	IF	CITATIONS
1	Anticancer and chemosensitization effects of cannabidiol in 2D and 3D cultures of TNBC: involvement of GADD45, integrin- α 5, - β 25, - β 21, and autophagy. <i>Drug Delivery and Translational Research</i> , 2022, , 1.	3.0	6
2	Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents. <i>International Immunopharmacology</i> , 2022, 107, 108693.	1.7	18
3	Combined Transcriptomic and Proteomic Profiling to Unravel Osimertinib, CARP-1 Functional Mimetic (CFM 4.17) Formulation and Telmisartan Combo Treatment in NSCLC Tumor Xenografts. <i>Pharmaceutics</i> , 2022, 14, 1156.	2.0	4
4	Enhancement of transdermal permeation of cannabinoids and their pharmacodynamic evaluation in rats. <i>International Journal of Pharmaceutics</i> , 2022, 624, 122016.	2.6	8
5	Role of nano-lipid formulation of CARP-1 mimetic, CFM-4.17 to improve systemic exposure and response in osimertinib resistant non-small cell lung cancer. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 158, 172-184.	2.0	9
6	Cytotoxic and chemosensitizing effects of glycoalkaloidic extract on 2D and 3D models using RT4 and patient derived xenografts bladder cancer cells. <i>Materials Science and Engineering C</i> , 2021, 119, 111460.	3.8	14
7	Sustained release dosage form of noscapine HCl using hot melt extrusion (HME) technique: formulation and pharmacokinetics. <i>Drug Delivery and Translational Research</i> , 2021, 11, 1156-1165.	3.0	3
8	Role of Exosomes for Delivery of Chemotherapeutic Drugs. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2021, 38, 53-97.	1.2	35
9	Role of In Vitro Models for Development of Ophthalmic Delivery Systems. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2021, 38, 1-31.	1.2	9
10	Synergistic effects of methyl 2-cyano-3,11-dioxo-18beta-olean-1,-12-dien-30-oate and erlotinib on erlotinib-resistant non-small cell lung cancer cells. <i>Journal of Pharmaceutical Analysis</i> , 2021, 11, 799-807.	2.4	5
11	Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2021, 41, 4215-4228.	0.5	7
12	Cannabidiol loaded extracellular vesicles sensitize triple-negative breast cancer to doxorubicin in both in-vitro and in vivo models. <i>International Journal of Pharmaceutics</i> , 2021, 607, 120943.	2.6	27
13	Polysaccharide hydrogel based 3D printed tumor models for chemotherapeutic drug screening. <i>Scientific Reports</i> , 2021, 11, 372.	1.6	45
14	Rapamycin Eyedrops Increased CD4+Foxp3+ Cells and Prevented Goblet Cell Loss in the Aged Ocular Surface. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8890.	1.8	8
15	Advances in Translational Nanotechnology: Challenges and Opportunities. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 4881.	1.3	6
16	High-throughput 3D bioprinting of corneal stromal equivalents. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2020, 108, 2981-2994.	1.6	41
17	The Role of Self-Nanoemulsifying Drug Delivery Systems of CDODA-Me in Sensitizing Erlotinib-Resistant Non-Small Cell Lung Cancer. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 1867-1882.	1.6	16
18	Targeting lung cancer stem cells using combination of Tel and Docetaxel liposomes in 3D cultures and tumor xenografts. <i>Toxicology and Applied Pharmacology</i> , 2020, 401, 115112.	1.3	18

#	ARTICLE	IF	CITATIONS
19	Amorphous solid dispersions: An update for preparation, characterization, mechanism on bioavailability, stability, regulatory considerations and marketed products. <i>International Journal of Pharmaceutics</i> , 2020, 586, 119560.	2.6	168
20	DLP 3D Printed "Intelligent" Microneedle Array (i-i)¼NA) for Stimuli Responsive Release of Drugs and Its <i>in Vitro</i> and <i>ex Vivo</i> Characterization. <i>Journal of Microelectromechanical Systems</i> , 2020, 29, 685-691.	1.7	21
21	Withaferin A reverses bile duct ligation-induced liver fibrosis by modulating extracellular matrix deposition: Role of LOXL2/Snail1, vimentin, and NF κ B signaling. <i>BioFactors</i> , 2019, 45, 959-974.	2.6	14
22	Combination of UVB Absorbing Titanium Dioxide and Quercetin Nanogel for Skin Cancer Chemoprevention. <i>AAPS PharmSciTech</i> , 2019, 20, 240.	1.5	17
23	Chemosensitizing Effect of Cernumidine Extracted from <i>Solanum cernuum</i> on Bladder Cancer Cells <i>in Vitro</i> . <i>Chemistry and Biodiversity</i> , 2019, 16, e1900334.	1.0	11
24	Whole-Eye Perfusion Model for Screening of the Ocular Formulations via Confocal Laser Scanning Microscopy. <i>AAPS PharmSciTech</i> , 2019, 20, 307.	1.5	5
25	Withaferin A ameliorates renal injury due to its potent effect on inflammatory signaling. <i>BioFactors</i> , 2019, 45, 750-762.	2.6	20
26	Cationic lipoplexes for treatment of cancer stem cell-derived murine lung tumors. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 18, 31-43.	1.7	12
27	Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells. <i>AAPS PharmSciTech</i> , 2019, 20, 135.	1.5	18
28	Formulation of topical ibuprofen solid lipid nanoparticle (SLN) gel using hot melt extrusion technique (HME) and determining its anti-inflammatory strength. <i>Drug Delivery and Translational Research</i> , 2019, 9, 816-827.	3.0	37
29	Characterization and printability of Sodium alginate -Gelatin hydrogel for bioprinting NSCLC co-culture. <i>Scientific Reports</i> , 2019, 9, 19914.	1.6	106
30	Actinomycin D and Telmisartan Combination Targets Lung Cancer Stem Cells Through the Wnt/Beta Catenin Pathway. <i>Scientific Reports</i> , 2019, 9, 18177.	1.6	21
31	Tacrolimus Loaded PEG-Cholecalciferol Based Micelles for Treatment of Ocular Inflammation. <i>Pharmaceutical Research</i> , 2018, 35, 117.	1.7	20
32	Cholecalciferol-PEG Conjugate-Based Nanomicelles of Doxorubicin for Treatment of Triple-Negative Breast Cancer. <i>AAPS PharmSciTech</i> , 2018, 19, 792-802.	1.5	26
33	Drug delivery strategies for chemoprevention of <i>UVB</i> -induced skin cancer: A review. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2018, 34, 60-68.	0.7	21
34	Development of Hot Melt Extruded Solid Dispersion of Tamoxifen Citrate and Resveratrol for Synergistic Effects on Breast Cancer Cells. <i>AAPS PharmSciTech</i> , 2018, 19, 3287-3297.	1.5	25
35	A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers. <i>Oncotarget</i> , 2018, 9, 29680-29697.	0.8	11
36	Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment. <i>Journal of Controlled Release</i> , 2017, 246, 120-132.	4.8	61

#	ARTICLE	IF	CITATIONS
37	Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC). <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 153, 208-219.	2.5	49
38	Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer. <i>Pharmaceutical Research</i> , 2017, 34, 2371-2384.	1.7	27
39	Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer. <i>Scientific Reports</i> , 2017, 7, 15824.	1.6	31
40	Smart thermosensitive liposomes for effective solid tumor therapy and in vivo imaging. <i>PLoS ONE</i> , 2017, 12, e0185116.	1.1	24
41	CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers. <i>Oncotarget</i> , 2016, 7, 73370-73388.	0.8	11
42	Overview on Therapeutic Applications of Microparticulate Drug Delivery Systems. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2016, 33, 309-361.	1.2	72
43	Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer. <i>Experimental Cell Research</i> , 2016, 346, 65-73.	1.2	29
44	Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer. <i>Nanomedicine</i> , 2016, 11, 1377-1392.	1.7	40
45	NR4A1 Antagonists Inhibit β 1-Integrin-Dependent Breast Cancer Cell Migration. <i>Molecular and Cellular Biology</i> , 2016, 36, 1383-1394.	1.1	49
46	Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer. <i>Molecular Pharmaceutics</i> , 2016, 13, 2049-2058.	2.3	39
47	Novel diindolylmethane derivatives based NLC formulations to improve the oral bioavailability and anticancer effects in triple negative breast cancer. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 108, 168-179.	2.0	35
48	Lipid-based oral delivery systems for skin deposition of a potential chemopreventive DIM derivative: characterization and evaluation. <i>Drug Delivery and Translational Research</i> , 2016, 6, 526-539.	3.0	7
49	Ultra-flexible nanocarriers for enhanced topical delivery of a highly lipophilic antioxidative molecule for skin cancer chemoprevention. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 143, 156-167.	2.5	29
50	Percutaneous delivery of α -melanocyte-stimulating hormone for the treatment of imiquimod-induced psoriasis. <i>Journal of Drug Targeting</i> , 2016, 24, 537-547.	2.1	12
51	Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer. <i>Drug Delivery</i> , 2016, 23, 1232-1241.	2.5	49
52	Alginate-Chitosan-Based 3D Cell Culture System as an In Vitro Tumor Model: An Important Tool in Cancer Research. <i>Methods in Molecular Biology</i> , 2016, 1379, 117-128.	0.4	18
53	Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma. <i>Pharmaceutical Research</i> , 2016, 33, 137-154.	1.7	32
54	Nuclear receptor 4A (NR4A) family "orphans" no more. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 157, 48-60.	1.2	149

#	ARTICLE	IF	CITATIONS
55	Formulation, Pharmacokinetic, and Efficacy Studies of Mannosylated Self-Emulsifying Solid Dispersions of Noscapine. PLoS ONE, 2016, 11, e0146804.	1.1	12
56	Nuclear receptor 4A1 (NR4A1) as a drug target for treating rhabdomyosarcoma (RMS). Oncotarget, 2016, 7, 31257-31269.	0.8	23
57	Pharmacokinetic, biodistribution and therapeutic efficacy of 5-fluorouracil-loaded pH-sensitive PEGylated liposomal nanoparticles in HCT-116 tumor bearing mouse. Journal of Nature and Science, 2016, 2, .	1.1	6
58	Identification and Testing of Novel CARP-1 Functional Mimetic Compounds as Inhibitors of Non-Small Cell Lung and Triple Negative Breast Cancers. Journal of Biomedical Nanotechnology, 2015, 11, 1608-1627.	0.5	18
59	Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer. Journal of Pharmaceutical Sciences, 2015, 104, 4417-4426.	1.6	53
60	Lipid Nanocarriers of a Lipid-Conjugated Estrogenic Derivative Inhibit Tumor Growth and Enhance Cisplatin Activity against Triple-Negative Breast Cancer: Pharmacokinetic and Efficacy Evaluation. Molecular Pharmaceutics, 2015, 12, 1105-1120.	2.3	60
61	Evaluation of Spray BIO-Max DIM-P in Dogs for Oral Bioavailability and in Nu/nu Mice Bearing Orthotopic/Metastatic Lung Tumor Models for Anticancer Activity. Pharmaceutical Research, 2015, 32, 2292-2300.	1.7	10
62	Evaluation of self-emulsified DIM-14 in dogs for oral bioavailability and in Nu/nu mice bearing stem cell lung tumor models for anticancer activity. Journal of Controlled Release, 2015, 213, 18-26.	4.8	11
63	Doxorubicin liposomes as an investigative model to study the skin permeation of nanocarriers. International Journal of Pharmaceutics, 2015, 489, 106-116.	2.6	47
64	Enhanced Percutaneous Delivery of 1,1-bis(3-indolyl)-1-(p-chlorophenyl) Methane for Skin Cancer Chemoprevention. Journal of Biomedical Nanotechnology, 2015, 11, 1269-1281.	0.5	8
65	Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy. Endocrine-Related Cancer, 2015, 22, 831-840.	1.6	51
66	Nanomiengel - A Novel Drug Delivery System for Topical Application - In Vitro and In Vivo Evaluation. PLoS ONE, 2014, 9, e115952.	1.1	58
67	Approaches to Improve the Oral Bioavailability and Effects of Novel Anticancer Drugs Berberine and Betulinic Acid. PLoS ONE, 2014, 9, e89919.	1.1	113
68	CARP-1 Functional Mimetics Are a Novel Class of Small Molecule Inhibitors of Malignant Pleural Mesothelioma Cells. PLoS ONE, 2014, 9, e89146.	1.1	17
69	Mechanisms of Neuroblastoma Cell Growth Inhibition by CARP-1 Functional Mimetics. PLoS ONE, 2014, 9, e102567.	1.1	12
70	Effect of combination of hydrophilic and lipophilic permeation enhancers on the skin permeation of kahalalide F. Journal of Pharmacy and Pharmacology, 2014, 66, 760-768.	1.2	8
71	Epithelial transport of Noscapine across cell monolayer and influence of absorption enhancers on <i>in vitro</i> permeation and bioavailability: implications for intestinal absorption. Journal of Drug Targeting, 2014, 22, 498-508.	2.1	8
72	Topical administration of dual siRNAs using fusogenic lipid nanoparticles for treating psoriatic-like plaques. Nanomedicine, 2014, 9, 2157-2174.	1.7	49

#	ARTICLE	IF	CITATIONS
73	EphA2 Targeting Pegylated Nanocarrier Drug Delivery System for Treatment of Lung Cancer. <i>Pharmaceutical Research</i> , 2014, 31, 2796-2809.	1.7	35
74	Opening Up the Optical Imaging Window Using Nano-Luciferin. <i>Pharmaceutical Research</i> , 2014, 31, 3073-3084.	1.7	9
75	Theranostic tumor homing nanocarriers for the treatment of lung cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, e1053-e1063.	1.7	19
76	Cationic lipid guided short-hairpin RNA interference of annexin A2 attenuates tumor growth and metastasis in a mouse lung cancer stem cell model. <i>Journal of Controlled Release</i> , 2014, 184, 67-78.	4.8	46
77	³¹ P solid-state NMR based monitoring of permeation of cell penetrating peptides into skin. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 190-199.	2.0	14
78	Investigation of Follicular and Non-follicular Pathways for Polyarginine and Oleic Acid-Modified Nanoparticles. <i>Pharmaceutical Research</i> , 2013, 30, 1037-1049.	1.7	51
79	1,1-Bis (3- ϵ -indolyl)-1-(p-substitutedphenyl)methane compounds inhibit lung cancer cell and tumor growth in a metastasis model. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 50, 227-241.	1.9	41
80	Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models. <i>Journal of Controlled Release</i> , 2013, 172, 86-95.	4.8	66
81	Efficacy of Aerosolized Celecoxib Encapsulated Nanostructured Lipid Carrier in Non-small Cell Lung Cancer in Combination with Docetaxel. <i>Pharmaceutical Research</i> , 2013, 30, 1435-1446.	1.7	55
82	Topical delivery of anti-TNF α siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo. <i>Journal of Controlled Release</i> , 2013, 170, 51-63.	4.8	149
83	Chemoprevention of Skin Cancer with 1,1-Bis (3- ϵ -Indolyl)-1-(Aromatic) Methane Analog through Induction of the Orphan Nuclear Receptor, NR4A2 (Nurr1). <i>PLoS ONE</i> , 2013, 8, e69519.	1.1	15
84	Design, Synthesis of Novel Lipids as Chemical Permeation Enhancers and Development of Nanoparticle System for Transdermal Drug Delivery. <i>PLoS ONE</i> , 2013, 8, e82581.	1.1	35
85	AlgiMatrix TM Based 3D Cell Culture System as an In-Vitro Tumor Model for Anticancer Studies. <i>PLoS ONE</i> , 2013, 8, e53708.	1.1	189
86	The nuclear receptor TR3 regulates mTORC1 signaling in lung cancer cells expressing wild-type p53. <i>Oncogene</i> , 2012, 31, 3265-3276.	2.6	100
87	Dermal Microdialysis Technique to Evaluate the Trafficking of Surface-Modified Lipid Nanoparticles upon Topical Application. <i>Pharmaceutical Research</i> , 2012, 29, 2587-2600.	1.7	42
88	Pharmacokinetic evaluation and In Vitro-In Vivo Correlation (IVIVC) of novel methylene-substituted 3,3- ϵ diindolymethane (DIM). <i>European Journal of Pharmaceutical Sciences</i> , 2012, 46, 8-16.	1.9	21
89	Effect of oleic acid modified polymeric bilayered nanoparticles on percutaneous delivery of spantide II and ketoprofen. <i>Journal of Controlled Release</i> , 2012, 158, 336-345.	4.8	76
90	Enhanced skin permeation using polyarginine modified nanostructured lipid carriers. <i>Journal of Controlled Release</i> , 2012, 161, 735-745.	4.8	105

#	ARTICLE	IF	CITATIONS
91	Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer. <i>Lung Cancer</i> , 2011, 71, 271-282.	0.9	106
92	Nose-to-brain transport of melatonin from polymer gel suspensions: a microdialysis study in rats. <i>Journal of Drug Targeting</i> , 2011, 19, 731-740.	2.1	22
93	Enhanced Anticancer Activity of Gemcitabine in Combination with Noscapine via Antiangiogenic and Apoptotic Pathway against Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2011, 6, e27394.	1.1	39
94	Antitumor Activity of Noscapine in Combination with Doxorubicin in Triple Negative Breast Cancer. <i>PLoS ONE</i> , 2011, 6, e17733.	1.1	93
95	Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 56, 899-907.	1.2	30
96	Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. <i>Journal of Controlled Release</i> , 2010, 144, 233-241.	4.8	197
97	Inhalation Delivery of a Novel Diindolymethane Derivative for the Treatment of Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 3003-3014.	1.9	29
98	Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. <i>Molecular Membrane Biology</i> , 2010, 27, 247-259.	2.0	328
99	Evaluation of EpiDerm full thickness-300 (EFT-300) as an in vitro model for skin irritation: Studies on aliphatic hydrocarbons. <i>Toxicology in Vitro</i> , 2010, 24, 669-676.	1.1	29
100	Preformulation stability of Spantide II, a promising topical anti-inflammatory agent for the treatment of psoriasis and contact dermatitis. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 56, 19-25.	1.2	16
101	Dermal microdialysis of inflammatory markers induced by aliphatic hydrocarbons in rats. <i>Toxicology Letters</i> , 2009, 185, 168-174.	0.4	11
102	Nanoliposomal Dry Powder Formulations. <i>Methods in Enzymology</i> , 2009, 464, 167-191.	0.4	20
103	Enhancement of Docetaxel Anticancer Activity by a Novel Diindolymethane Compound in Human Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 543-552.	3.2	102
104	Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 63, 117-126.	1.1	81
105	Effect of Cyclodextrins on the Complexation and Nasal Permeation of Melatonin. <i>Drug Delivery</i> , 2008, 15, 381-388.	2.5	39
106	Ganciclovir augments the lytic induction and apoptosis induced by chemotherapeutic agents in an Epstein-Barr virus-infected gastric carcinoma cell line. <i>Anti-Cancer Drugs</i> , 2007, 18, 79-85.	0.7	49
107	Estimation of proinflammatory biomarkers of skin irritation by dermal microdialysis following exposure with irritant chemicals. <i>Toxicology</i> , 2007, 237, 77-88.	2.0	26
108	In vitro and in vivo comparison of dermal irritancy of jet fuel exposure using EpiDerm (EPI-200) cultured human skin and hairless rats. <i>Toxicology Letters</i> , 2006, 167, 85-94.	0.4	27

#	ARTICLE	IF	CITATIONS
109	Inhalation Delivery and Anti-tumor Activity of Celecoxib in Human Orthotopic Non-Small Cell Lung Cancer Xenograft Model. <i>Pharmaceutical Research</i> , 2006, 23, 2094-2106.	1.7	58
110	Brownian Diffusion and Surface Kinetics of Liposome and Viral Particle Uptake by Human Lung Cancer Cells In-Vitro. <i>Annals of Biomedical Engineering</i> , 2006, 34, 1573-1586.	1.3	7
111	Stability and degradation profiles of Spantide II in aqueous solutions. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 27, 158-166.	1.9	8
112	Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. <i>International Journal of Cancer</i> , 2006, 118, 396-404.	2.3	51
113	In vitro and in vivo evaluation of topical formulations of Spantide II. <i>AAPS PharmSciTech</i> , 2005, 6, E565-E572.	1.5	53
114	Box-Behnken experimental design in the development of a nasal drug delivery system of model drug hydroxyurea: Characterization of viscosity, in vitro drug release, droplet size, and dynamic surface tension. <i>AAPS PharmSciTech</i> , 2005, 6, E573-E585.	1.5	43
115	The effect of occlusive and unocclusive exposure to xylene and benzene on skin irritation and molecular responses in hairless rats. <i>Archives of Toxicology</i> , 2005, 79, 294-301.	1.9	11
116	Formulation and Evaluation of Aerosolized Celecoxib for the Treatment of Lung Cancer. <i>Pharmaceutical Research</i> , 2005, 22, 427-439.	1.7	22
117	Effect of methyl substitution of benzene on the percutaneous absorption and skin irritation in hairless rats. <i>Toxicology Letters</i> , 2005, 159, 261-271.	0.4	27
118	Effect of a Selective Cyclooxygenase-2 Inhibitor, Nimesulide, on the Growth of Lung Tumors and Their Expression of Cyclooxygenase-2 and Peroxisome Proliferator- Activated Receptor- β . <i>Clinical Cancer Research</i> , 2004, 10, 1521-1529.	3.2	53
119	Percutaneous absorption and skin irritation upon low-level prolonged dermal exposure to nonane, dodecane and tetradecane in hairless rats. <i>Toxicology and Industrial Health</i> , 2004, 20, 109-118.	0.6	25
120	Percutaneous Absorption and Anti-Inflammatory Effect of a Substance P Receptor Antagonist: Spantide II. <i>Pharmaceutical Research</i> , 2004, 21, 108-113.	1.7	23
121	Evaluation of the Malvern Spraytec [®] with inhalation cell for the measurement of particle size distribution from metered dose inhalers. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 349-363.	1.6	36
122	Evaluation of different parameters that affect droplet size distribution from nasal sprays using the Malvern Spraytec [®] . <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 1725-1742.	1.6	82
123	Formulation and In Vitro Evaluation of Transdermal Patches of Melatonin. <i>Drug Development and Industrial Pharmacy</i> , 2004, 30, 205-212.	0.9	43
124	Inhalation Delivery of Anticancer Agents via HFA-Based Metered Dose Inhaler Using Methotrexate as a Model Drug. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2002, 15, 261-270.	1.2	16
125	Effect of vehicles on the transdermal delivery of melatonin across porcine skin in vitro. <i>Journal of Controlled Release</i> , 2002, 83, 307-311.	4.8	45
126	Skin permeation enhancement effect and skin irritation of saturated fatty alcohols. <i>International Journal of Pharmaceutics</i> , 2002, 248, 219-228.	2.6	113

#	ARTICLE	IF	CITATIONS
127	Effect of jet fuels on the skin morphology and irritation in hairless rats. <i>Toxicology</i> , 2002, 175, 35-47.	2.0	35
128	Percutaneous permeation and skin irritation of JP-8+100 jet fuel in a porcine model. <i>Toxicology Letters</i> , 2001, 119, 133-142.	0.4	17
129	Stealth monensin immunoliposomes as potentiator of immunotoxins in vitro. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2001, 52, 13-20.	2.0	17
130	Percutaneous absorption and skin irritation of JP-8 (jet fuel). <i>Toxicology</i> , 2001, 161, 1-11.	2.0	41
131	Conjugation of anti-My9 antibody to stealth monensin liposomes and the effect of conjugated liposomes on the cytotoxicity of immunotoxin. <i>Journal of Controlled Release</i> , 2001, 76, 285-295.	4.8	13
132	Evaluation of skin sensitization potential of melatonin and nimesulide by murine local lymph node assay. <i>European Journal of Pharmaceutical Sciences</i> , 2001, 14, 217-220.	1.9	17
133	Evaluation of skin sensitization potential of jet fuels by murine local lymph node assay. <i>Toxicology Letters</i> , 2000, 116, 165-170.	0.4	25
134	Encapsulation, Stability, and In Vitro Release Characteristics of Liposomal Formulations of Stavudine (D4T). <i>Drug Delivery</i> , 1999, 6, 31-37.	2.5	10
135	Stealth monensin liposomes as a potentiator of adriamycin in cancer treatment. <i>Journal of Controlled Release</i> , 1999, 59, 43-53.	4.8	22
136	Optimization of a vehicle mixture for the transdermal delivery of melatonin using artificial neural networks and response surface method. <i>Journal of Controlled Release</i> , 1999, 61, 71-82.	4.8	43
137	Lipophilic drug derivatives in liposomes. <i>International Journal of Pharmaceutics</i> , 1998, 165, 129-168.	2.6	198
138	Drug targeting systems for cancer chemotherapy. <i>Expert Opinion on Investigational Drugs</i> , 1998, 7, 1849-1864.	1.9	43
139	A modified HPLC method for monensin analysis in liposomes and nanocapsules and its comparison with spectrophotometric and radioactive methods. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1997, 15, 1775-1780.	1.4	8
140	Trends in Drug Targeting for Cancer Treatment. <i>Drug Delivery</i> , 1996, 3, 289-304.	2.5	13
141	Long circulating liposomes of 2',3'-dideoxyinosine: Formulation and stability. <i>Drug Delivery</i> , 1996, 3, 279-287.	2.5	3
142	Potential of ricin A immunotoxin by monoclonal antibody targeted monensin containing small unilamellar vesicles. <i>Cancer Letters</i> , 1994, 84, 15-21.	3.2	22
143	Regression of human melanoma xenografts in nude mice injected with methotrexate linked to monoclonal antibody 225.28 to human high molecular weight-melanoma associated antigen. <i>Cancer Immunology, Immunotherapy</i> , 1991, 34, 90-96.	2.0	19
144	Freeze substitution technique for identifying liposomes incorporated in emulsion and gel preparations. <i>Journal of Microencapsulation</i> , 1990, 7, 77-84.	1.2	2

#	ARTICLE	IF	CITATIONS
145	Antibody directed targeting of methotrexate-containing small unilamellar vesicles. Cancer Immunology, Immunotherapy, 1988, 27, 17-25.	2.0	12